株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

創薬アウトソーシングの世界市場:2028年までの予測

Global Drug Discovery Outsourcing Market Forecast to 2028: Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening

発行 Visiongain Ltd 商品コード 260308
出版日 ページ情報 英文 195 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=140.72円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
創薬アウトソーシングの世界市場:2028年までの予測 Global Drug Discovery Outsourcing Market Forecast to 2028: Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening
出版日: 2019年04月16日 ページ情報: 英文 195 Pages
概要

世界の創薬アウトソーシング市場は、2018年に226億9000万米ドルに達しました。市場は、今後5年間のCAGR (複合年間成長率) で、11.7%の成長が予測されています。

当レポートでは、世界の創薬アウトソーシング市場について調査分析し、収益予測に焦点を当てて、将来のビジネス機会、主要促進要因、市場に影響を与える課題、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 創薬アウトソーシングのイントロダクション

  • アウトソーシングとは
  • 創薬アウトソーシングとは
  • 創薬をアウトソーシングする理由
  • 一般的な創薬モデル (産学協同を含む)
  • 創薬のアウトソーシングモデルがイノベーションを牽引
  • 創薬におけるアウトソーシングプロセス
  • 創薬アウトソーシングにおける課題
  • 新興市場はCROに人気
  • 買収に向けた戦略的提携
  • 最新の創薬アウトソーシング契約

第3章 世界の創薬アウトソーシング市場・サービス分野の二次市場:市場予測

  • 創薬アウトソーシング:世界市場の概要
  • 世界の創薬アウトソーシング市場:収益予測
  • 世界の創薬アウトソーシング市場 (サービスタイプ別) :収益予測
  • 世界の創薬アウトソーシング市場 (地域別) :収益予測

第4章 世界の創薬アウトソーシング市場 (サービスタイプ別) :予測

  • 世界の創薬アウトソーシング市場 (サービスタイプ別) :収益予測
  • 化学サービス
  • 生物学サービス
  • リード化合物最適化
  • リード化合物探索・スクリーニング

第5章 世界の創薬アウトソーシング市場 (地域別、国別) :予測

  • 創薬アウトソーシングの概要
  • 創薬アウトソーシング市場における主要国市場の予測
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第6章 創薬アウトソーシング市場における主要企業

  • 創薬アウトソーシング:断片的・成長市場
  • 主要CROの特徴
  • 創薬アウトソーシング市場における主要企業のサービス提供
    • 企業リスト
    • Albany Molecular Research (AMRI)
    • Evotec AG
    • Aptuit
    • Cyprotex
    • Charles River Laboratories
    • WIL Research Laboratories LLC
    • Covance (Laboratory Corporation of Americaが買収)
    • Domainex
    • GenScript Biotech Corporation
    • Pharmaceutical Product Development (PPD)
    • QuintilesIMS (IQVIA)
    • Selcia
    • Viva Biotech (Shanghai) Ltd.
    • WuXi Apptec

第7章 創薬アウトソーシング市場の定性分析

  • 市場の促進要因・抑制要因
  • SWOT分析
  • ファイブフォース分析

第8章 結論

付録

図表

List of Tables

  • Table 2.1: Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2017
  • Table 2.2: Selected Drug Discovery Outsourcing Alliances, 2013-2018
  • Table 3.1: PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn), 1980-2016
  • Table 3.2: Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), AGR (%), and CAGR (%) 2018-2028
  • Table 3.3: Global Drug Discovery Outsourcing Market by Service Type: Revenue ($mn), AGR (%) and CAGR (%) 2017-2028
  • Table 3.4: Global Drug Discovery Outsourcing Market by Leading Nationals: Revenue ($m), AGR (%) and CAGR (%), 2018-2028
  • Table 4.1: Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Service Type, 2017, 2023, 2028
  • Table 4.2: Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 4.3: Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 4.4: Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 4.5: Selected Source for Lead Compounds
  • Table 4.6: Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.1: Global Drug Discovery Outsourcing Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028
  • Table 5.2: North America Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.3: North America Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.4: US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.5: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.6: Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.7: Europe Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.8: Europe Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.9: Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.10: France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.11: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
  • Table 5.12: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.13: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.14: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
  • Table 5.15: Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.16: Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.17: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.18: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.19: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.20: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.21: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.22: LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.23: LAMEA Drug Discovery Outsourcing Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.24: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.25: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 5.26: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
  • Table 6.1: List of Key Participating Players
  • Table 6.2: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016
  • Table 6.3: AMRI: Service Offerings and Descriptions, 2017
  • Table 6.4: Evotec: Revenue and R&D Expenses ($m), 2013-2017
  • Table 6.5: Evotec AG Forecast: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 6.6: Selected Cyprotex Partnerships, 2015
  • Table 6.7: Charles River Laboratories: Historical Revenue ($m), 2013-2017
  • Table 6.8: Charles River Laboratories: Revenue ($m) by Segment, 2015-2017
  • Table 6.9: Charles River Laboratories: Revenue & %Change, 2015-2017
  • Table 6.10: Charles River Laboratories Forecast: Revenue ($m), AGR (%), CAGR (%), 2018-2028
  • Table 6.11: Covance: Historical Revenue ($bn), 2010-2013
  • Table 6.12: LabCorp: Historical Revenue ($m), 2014-2017
  • Table 6.13: Domainex Selected Collaborations
  • Table 6.14: Domainex: Drug Pipeline by Indication, 2018
  • Table 6.15: GenScript: Business Segments
  • Table 6.16: GenScript: Revenue by Business Segments ($m, %), 2016 & 2017
  • Table 6.17: QuintilesIMS: Revenue ($m) & AGR (%), 2013-2017
  • Table 6.18: QuintilesIMS Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2028
  • Table 6.19: Viva Biotech: Service Offerings
  • Table 6.20: WuXi AppTec: Historical Revenue ($m), By Business Segments, 2010-2014
  • Table 7.1: SWOT Analysis of the Drug Discovery Outsourcing Industry, 2017-2027
  • Table 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), CAGR (%), 2017, 2023 & 2028
  • Table 8.2: Global Drug Discovery Outsourcing Market, Revenue ($m) by Service Type, 2017, 2023, 2028

List of Figures

  • Figure 2.1: Selected Tasks being Outsourced in the Pharma Industry, 2017
  • Figure 2.2: Stages of the Drug Development Cycle
  • Figure 3.1: PhMRA's Historical Estimate for its Member's Total R&D Spending ($bn), 2000-2016
  • Figure 3.2: Attrition Rate of Compounds at the Developmental Stages
  • Figure 3.3: Global Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 4.1: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2018
  • Figure 4.2: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2023
  • Figure 4.3: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Service Type, 2028
  • Figure 4.4: Global Drug Discovery Outsourcing Market Revenue ($m) by Service Type, 2018-2028
  • Figure 4.5: Global Drug Discovery Outsourcing Market: Chemistry Services Revenue ($m), AGR (%), 2018-2028
  • Figure 4.6: Global Drug Discovery Outsourcing Market: Biology Services Revenue ($m), AGR (%), 2018-2028
  • Figure 4.7: An Overview of ADMET Screening in Drug Discovery
  • Figure 4.8: Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue ($m), AGR (%), 2017-2028
  • Figure 4.8: Typical Steps in the Lead Screening Process
  • Figure 4.9: Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue ($m), AGR (%), 2018-2028
  • Figure 5.1: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2017
  • Figure 5.2: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2023
  • Figure 5.3: The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2028
  • Figure 5.4: Global Drug Discovery Outsourcing Market Revenue ($m) by Leading Nationals, 2018-2028
  • Figure 5.5: US Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.6: Canada Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.7: Mexico Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.8: Germany Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.9: France Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.10: United Kingdom Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.11: Italy Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.12: Spain Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.13: Russia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.14: Japan Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2017-2028
  • Figure 5.15: China Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.16: Australia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.17: South Korea Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.18: India Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.19: Brazil Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.20: Saudi Arabia Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 5.21: Republic of South Africa Drug Discovery Outsourcing Market: Revenue ($m), AGR (%), 2018-2028
  • Figure 6.1: Albany Molecular Research (AMRI): Historical Revenue ($m), 2013-2016
  • Figure 6.2: Evotec AG Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.3: Charles River Laboratories: Historical Revenue ($m), 2013-2017
  • Figure 6.4: Charles River Laboratories: Revenue Share (%) by Segment, 2017
  • Figure 6.5: Charles River Laboratories: Revenue & %Change, 2015-2017
  • Figure 6.6: Charles River Laboratories Forecast: Revenue ($m), AGR (%), 2017-2028
  • Figure 6.7: Covance: Historical Revenue ($m), 2010-2013
  • Figure 6.8: Covance: Revenue Share (%) by Segment, 2013
  • Figure 6.9: LabCorp: Historical Revenue ($m), 2014-2017
  • Figure 6.10: LabCorp: Revenue Share (%) by Segment, 2017
  • Figure 6.11: GenScript: Revenue by Business Segments (%), 2017
  • Figure 6.12: QuintilesIMS: Revenue ($m), 2013-2017
  • Figure 6.13: QuintilesIMS Forecast: Revenue ($bn), AGR (%), 2017-2028
  • Figure 7.1: The Drug Discovery Outsourcing Market: Drivers and Restraints, 2018-2028
  • Figure 7.2: Porter's Five Forces Analysis of the Companion Diagnostics Market, 2018-2028
  • Figure 8.1: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m), 2017, 2023, 2028
  • Figure 8.2: The Global Drug Discovery Outsourcing Market Forecast: Revenue ($m) by Service Type, 2017, 2023, 2028

COMPANIES LISTED:

  • Acurian
  • Advion Bioanalytical Labs
  • Albany Molecular Research, Inc. (AMRI)
  • Alexion
  • Almirall, S.A.
  • Antengene Corporation
  • Anthem Bio Science
  • Apredica
  • Aptuit
  • Argenta
  • Ark Therapeutics
  • Asclepia
  • Astex
  • AstraZeneca
  • Aurora Fine Chemicals
  • Auspherix
  • AutoGenomics
  • Awridian
  • Bayer AG
  • Behrman Capital
  • Bio Pontis Alliance
  • BioCity
  • BioDuro
  • BioFocus
  • Bioversys AG
  • Boehringer Ingelheim
  • Brains On-Line
  • Bristol Myers Squibb
  • Bruker Daltonics
  • C4XDiscovery
  • Caprion Proteomics
  • Carna Biosciences, Inc.
  • CAS
  • Celgene Corporation
  • CENTOGENE AG
  • ChanTest
  • Charles River Laboratories, Inc.
  • CHDI
  • Chiesi Farmaceutici
  • Chiltern International Group Limited
  • Chronos Therapeutics
  • CISYS LifeSciences
  • Covance, Inc. (Laboratory Corporation of America)
  • Crelux GmbH
  • Cresset Discovery Services
  • CRL
  • Cyprotex
  • Daiichi Sankyo
  • Dalton Pharma Services
  • DaVita Clinical Research
  • Domainex
  • Dotmatics
  • Drug Discovery Alliances, Inc.
  • Eisai Co., Ltd.
  • Elan
  • Eli Lilly and Company
  • EMBL
  • Enamine
  • ERT
  • Eurofins Scientific
  • Evidera
  • Evotec
  • Exquiron Biotech
  • Exscientia
  • Forma Therapeutics
  • Frenova Renal Research
  • Galapagos
  • GalapagosNV
  • Gilead Sciences, Inc.
  • Great Lakes Chemical Corp.
  • Hangzhou Tigermed Consulting
  • Haplogen GmbH
  • HD Biosciences
  • HealthCore, Inc.
  • Hellman & Friedman
  • HighRes Biosolutions
  • Horizon
  • Hypha Discovery
  • ICON PLC
  • iGEM
  • Imperial College London
  • InSphero
  • Janssen Pharmaceuticals Inc.
  • Johnson & Johnson
  • Johnson Matthey
  • JOINN Laboratories
  • Jubilant Lifesciences
  • Kellogg Company
  • Knopp Biosciences
  • KWS BioTest
  • Laurus Labs
  • Lonza
  • Mayo Clinic
  • MedImmune
  • Merck KGaA
  • Microbiologics
  • Midwest Bio Research
  • Moderna Therapeutics
  • Molecular Sensing, Inc.
  • MPI Research
  • Nimbus Therapeutics
  • NovaLead Pharma Pvt. Ltd.
  • Novo Nordisk
  • Ono Pharmaceutical Co. Ltd.
  • ORIG3N, Inc.
  • Paraxel
  • PathoQuest
  • Pelago Bioscience
  • Petra Pharma Corporation
  • Pharma Nest's Genesis
  • Pharmidex
  • Piramal Group
  • PPD
  • PRA International
  • Proteros Biostructures GmbH
  • QuintilesIMS
  • Quotient Sciences
  • Rahme Lab
  • Regulus Therapeutics Inc.
  • ResearchPoint Global (RPG)
  • Ricerca Biosciences LLC's
  • Roche
  • Rules-Based Medicines
  • SAMDI Tech. Inc.
  • Sanofi
  • SARomics Biostructures
  • Sciformix Corporation
  • Selvita
  • SenzaGen
  • Shang Pharma Corporation
  • Sharp Edge Labs, Inc
  • Shin Nippon Biomedical Laboratories Ltd.
  • Shionogi
  • Siena Biotech
  • Signature Discovery
  • Sirius Analytical
  • Solvo Biotechnology
  • STA Pharmaceutical Co., Ltd.
  • Synthesis MedChem
  • TESARO, Inc.
  • The Carlyle Group L.P. (Albany Molecular Research Inc.)
  • ThermoFisher Sceintific
  • UCB Pharma
  • Viva Biotech
  • Vivo Path
  • West Lafayette
  • WIL Research
  • WIL Research Laboratories LLC
  • WuXi App TecCo.
  • WuXi Apptec
  • X-Chem
  • XtalPi Inc.

List of Organizations Mentioned in the Report:

  • Academic Drug Discovery Consortium (ADDC)
  • Academy of Military Medical Sciences
  • Allegheny Health Network Research Institute in Pittsburgh, Duke University
  • AMRI
  • Babraham Institute
  • Blueprint Neurotherapeutics Network
  • Charité-Universitätsmedizin Berlin
  • Duke University
  • European CRO Federation
  • European Molecular Biology Laboratory (EMBL)
  • Fraunhofer Institute for Molecular Biology and Applied Ecology
  • Imperial College London
  • Indiana Clinical and Translational Sciences Institute
  • Marshall University
  • Massey Cancer Centre
  • Milner Therapeutics Institute
  • Molecular Surgical Laboratory of Massachusetts General Hospital
  • National Center for Advancing Translational Sciences
  • National Institute for Food and Drug Control
  • National Institute of Allergy and Infectious Disease (NIAID)
  • National Institutes of Health
  • Sanger Institute
  • the National Centre of Biomedical Analysis
  • University of California
  • University of Cambridge
  • University of Manchester
  • University of North Carolina
  • Virginia Commonwealth University, Richmond
目次
Product Code: PHA0413

The global drug discovery outsourcing market is estimated to have reach $22.69bn in 2018, dominated by the chemistry services segment. The global drug discovery outsourcing market is expected to grow at a CAGR of 11.7% in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 195-page report you will receive 114 charts - all unavailable elsewhere.

The 195-page report provides clear detailed insight into the global drug discovery outsourcing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Drug Discovery Outsourcing Market revenues forecasts to 2028

Global Drug Discovery Outsourcing Market revenues forecast to 2028 by Service Type:

  • Chemistry Services
  • Biology Services
  • Lead Optimisation
  • Lead Identification & Screening

Global Drug Discovery Outsourcing Market revenues forecast to 2028 by Regional and National Market:

  • North America: U.S, Canada, Mexico
  • Europe: Germany, France, UK, Italy, Spain, Russia, Rest of Europe
  • Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific
  • LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Rest of LAMEA

Each regional market is further segmented by submarket: chemistry services, biology services, lead optimisation, lead identification & screening.

This report profiles and discusses the selected leading companies:

  • Albany Molecular Research (AMRI)
  • Aptuit, LLC
  • Charles River Laboratories, Inc.
  • Covance, Inc.
  • Cyprotex plc
  • Domainex
  • Evotec AG
  • GenScript
  • IQVIA (QuintilesIMS)
  • Laboratory Corporation of America
  • Pharmaceutical Product Development (PPD)
  • Selcia
  • Viva Biotech
  • WIL Research Laboratories
  • WuXi AppTec

The report provides financial performance, service offerings, strategic moves & development, mergers & acquisitions.

A SWOT analysis and Porter's Five Forces Analysis of the Drug Discovery Outsourcing market.

Key Questions Answered by this Report:

  • How is the Drug Discovery Outsourcing Market evolving?
  • What are the drivers and restraints for the growth of the Drug Discovery Outsourcing Market?
  • How will each drug discovery outsourcing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2028?
  • How will the market shares for each drug discovery outsourcing submarket develop to 2028?
  • What is the value of the leading drug discovery outsourcing submarkets in important regions of the world?
  • What will be the main driver for the overall market to 2028?
  • How will the market shares of the national markets change by 2028 and which geographical region will lead the market by 2028?
  • Who are the leading players and what are their prospects over the forecast period?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Drug Discovery Outsourcing Market. You find data, trends and predictions.

Buy our report today Global Drug Discovery Outsourcing Market Forecast to 2028: Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Drug Discovery Outsourcing Market Overview
  • 1.2. Market Definition & Scope
  • 1.3. Overview of Findings
  • 1.4. Structure of the Report
  • 1.5. Why You Should Read This Report?
  • 1.6. Key Questions Answered by This Analytical Report
  • 1.7. How This Report Delivers
  • 1.8. Who is This Report For?
  • 1.9. Methodology
    • 1.9.1. Primary Research
    • 1.9.2. Secondary Research
    • 1.9.3. Market Evaluation & Forecasting Methodology
  • 1.10. Frequently Asked Questions (FAQ)
  • 1.11. Associated Visiongain Reports
  • 1.12. About Visiongain

2. An Introduction to Drug Discovery Outsourcing

  • 2.1. What is Outsourcing?
  • 2.2. What is Drug Discovery Outsourcing?
  • 2.3. Why Outsource Drug Discovery?
  • 2.4. A Common Drug Discovery Model Includes Pharmaceutical Organizations Collaborating with Academia
  • 2.5. The Outsource Model for Drug Development Increases Innovation
  • 2.6. Outsourced Processes in Drug Discovery
  • 2.7. Challenges with Drug Discovery Outsourcing
  • 2.8. Emerging Markets are a Popular Destination for CROs
  • 2.9. Strategic Partnerships to Acquisitions
  • 2.10. Recent Drug Development Outsourcing Agreements

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets: Market Forecast to 2028

  • 3.1. Drug Discovery Outsourcing: Global Market Overview
  • 3.2. The Global Drug Discovery Outsourcing Market: Revenue Forecast to 2028
  • 3.3. Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
  • 3.4. Global Drug Discovery Outsourcing Market by Region: Revenue Forecast to 2028

4. Global Drug Discovery Outsourcing Market by Service Type: Forecast to 2028

  • 4.1. The Global Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
  • 4.2. Chemistry Services
    • 4.2.1. Libraries
    • 4.2.2. Building Blocks
    • 4.2.3. Compound Synthesis
    • 4.2.4. Global Drug Discovery Outsourcing Market: Chemistry Services Revenue Forecast to 2028
  • 4.3. Biology Services
    • 4.3.1. Target Identification
    • 4.3.2. Target Validation
    • 4.3.3. Global Drug Discovery Outsourcing Market: Biology Services Revenue Forecast to 2028
  • 4.4. Lead Optimisation
    • 4.4.1. ADMET Screening: Prevents Late Stage Failure of Clinical Trials
    • 4.4.2. Global Drug Discovery Outsourcing Market: Lead Optimisation Revenue Forecast to 2028
  • 4.5. Lead Identification and Screening
    • 4.5.1. Methods of Screening in Drug Discovery
    • 4.5.2. Primary Screening
    • 4.5.3. Global Drug Discovery Outsourcing Market: Lead Identification and Screening Revenue Forecast to 2028

5. Global Drug Discovery Outsourcing Market by Regional and National Market: Forecast to 2028

  • 5.1. Drug Discovery Outsourcing Overview
  • 5.2. The Leading National Markets in the Drug Discovery Outsourcing Market Forecast to 2028
  • 5.3. North America
    • 5.3.1. North America Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
    • 5.3.2. North America Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
    • 5.3.3. US Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.3.3.1. Canada Drug Discovery Outsourcing Market, Revenue Forecast to 2028
      • 5.3.3.2. Mexico Drug Discovery Outsourcing Market: Revenue Forecast to 2028
  • 5.4. Europe
    • 5.4.1. Europe Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
    • 5.4.2. Europe Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
      • 5.4.2.1. Germany Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.4.2.2. France Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.4.2.3. United Kingdom Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.4.2.4. Italy Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.4.2.5. Spain Drug Discovery Outsourcing Market: Revenue Forecast to 2028
      • 5.4.2.6. Russia Drug Discovery Outsourcing Market: Revenue Forecast, 2018-2028
  • 5.5. Asia-Pacific
    • 5.5.1. Asia-Pacific Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
    • 5.5.2. Asia-Pacific Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
    • 5.5.3. Japan Drug Discovery Outsourcing Market: Revenue Forecast to 2028
    • 5.5.4. China Drug Discovery Outsourcing Market: Revenue Forecast to 2028
  • 5.5.4.1. Challenges to China's Growth
    • 5.5.5. Australia Drug Discovery Outsourcing Market: Revenue Forecast to 2028
    • 5.5.6. South Korea Drug Discovery Outsourcing Market: Revenue Forecast to 2028
    • 5.5.7. India Drug Discovery Outsourcing Market: Revenue Forecast to 2028
  • 5.6. LAMEA
    • 5.6.1LAMEA Drug Discovery Outsourcing Market by Service Type: Revenue Forecast to 2028
    • 5.6.2. LAMEA Drug Discovery Outsourcing Market by Country: Revenue Forecast to 2028
    • 5.6.3. Brazil Drug Discovery Outsourcing Market: Revenue Forecast to 2028
    • 5.6.4. Saudi Arabia Drug Discovery Outsourcing Market, Revenue Forecast to 2028
    • 5.6.5. Republic of South Africa Drug Discovery Outsourcing Market: Revenue Forecast to 2028

6. Leading Companies in Drug Discovery Outsourcing Market

  • 6.1. Drug Discovery Outsourcing: A Fragmented and Growing Marketplace
  • 6.2. Characteristics of Leading Contract Research Organisations
    • 6.2.1. A Highly Quality Workforce
    • 6.2.2. Emphasis on Intellectual Property Protection
    • 6.2.3. Long Term Working Relationship
    • 6.2.4. Success in Project Completion
    • 6.2.5. Internal Drug Discovery Programmes
  • 6.3. Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market
    • 6.3.1. List of Key Participating Players in Drug Discovery Outsourcing Market
    • 6.3.2. Albany Molecular Research (AMRI)
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Historical Sales and Financial Performance, 2013-2016
      • 6.3.2.3. AMRI's Drug Discovery Services
      • 6.3.2.4. Internal Portfolio of Drug Discovery and Development Programme Collaborations
    • 6.3.3. Evotec AG
      • 6.3.3.1. Evotec AG Financial Performance, 2013-2017
      • 6.3.3.2. Evotec AG Sales Forecast, 2018-2028
      • 6.3.3.3. Evotec AG Recent Strategic Moves & Development
        • 6.3.3.3.1. Partnership with Boehringer Ingelheim Pharma
        • 6.3.3.3.2. Collaboration with CHDI
        • 6.3.3.3.3. Collaboration with MedImmune
        • 6.3.3.3.4. Collaboration with UCB Pharma
        • 6.3.3.3.5. Collaboration with Janssen
        • 6.3.3.3.6. Partnership with Bayer Pharmaceuticals
        • 6.3.3.3.7. Partnership with AstraZeneca
        • 6.3.3.3.8. Partnership with Johnson & Johnson
        • 6.3.3.3.9. Partnership with Sanofi
        • 6.3.3.3.10. Extended Partnership with Evotec
        • 6.3.3.3.11. Collaboration with TESARO, Inc.
        • 6.3.3.3.12. Collaboration with Petra Pharma Corporation
        • 6.3.3.3.13. Collaboration with Carna Biosciences, Incorporated
        • 6.3.3.3.14. Collaboration with Celgene Corporation
        • 6.3.3.3.15. Partnership with Sanofi
        • 6.3.3.3.16. Collaboration with Bayer AG
        • 6.3.3.3.17. Partnership with Novo Nordisk
        • 6.3.3.3.18. Partnership with CENTOGENE AG
        • 6.3.3.3.19. Collaboration with Almirall, S.A.
    • 6.3.4. Aptuit
      • 6.3.4.1. INDIGO: Accelerating Early Drug Candidates
      • 6.3.4.2. Aptuit Clinical Trial Supplies
      • 6.3.4.3. Strategic Partnerships, Acquisitions and Divestitures
        • 6.3.4.3.1. Divestiture of Aseptic Clinical Manufacturing
        • 6.3.4.3.2. Partnership with Siena Biotech
        • 6.3.4.3.3. Aptuit's Extended Partnership with GSK for Verona Centre
        • 6.3.4.3.4. Partnership with Laurus Labs
        • 6.3.4.3.5. Collaboration with Celgene Corporation
        • 6.3.4.3.6. Partnership with Chronos Therapeutics
        • 6.3.4.3.7. Partnership with Chiesi Farmaceutici
        • 6.3.4.3.8. Collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH)
        • 6.3.4.3.9. Partnership with SAMDI Tech, Inc.
        • 6.3.4.3.10. Collaboration with Bioversys AG
        • 6.3.4.3.11. Partnership with Regulus Therapeutics Inc.
    • 6.3.5. Cyprotex
    • 6.3.6. Charles River Laboratories
      • 6.3.6.1. Historical Sales and Recent Financial Performance, 2013-2017
      • 6.3.6.2. Strategies: Charles River Laboratories
        • 6.3.6.2.1. Acquisition of Galapagos' CRO Services Division (BioFocus and Argenta)
        • 6.3.6.2.2. Acquisition of VivoPath
        • 6.3.6.2.3. Acquisition of ChanTest
        • 6.3.6.2.4. Partnership with The Milner Therapeutics Institute
        • 6.3.6.2.5. Partnership with Chiesi Farmaceutici SpA
        • 6.3.6.2.6. Partnership with Nimbus Therapeutics
        • 6.3.6.2.7. Partnership with Microbiologics
        • 6.3.6.2.8. Agreement with CAS
        • 6.3.6.2.9. Partnership Extension with Eisai Co., Ltd.
        • 6.3.6.2.10. Agreement with SenzaGen
        • 6.3.6.2.11. Acquisition of Brains On-Line
        • 6.3.6.2.12. Acquisition of KWS BioTest
        • 6.3.6.2.13. Acquisition of MPI Research
        • 6.3.6.2.14. Agreement with AstraZeneca
        • 6.3.6.2.15. Partnership Extension with PathoQuest
      • 6.3.6.3. Charles River Laboratories: Revenue and Financial Analysis, 2017
      • 6.3.6.4. Charles River Laboratories Sales Forecast, 2018-2028
    • 6.3.7. WIL Research Laboratories LLC
      • 6.3.7.1. Focus on Preclinical Research
      • 6.3.7.2. Acquisition of Midwest Bio Research
      • 6.3.7.3. Acquisition of Ricerca Biosciences LLC
    • 6.3.8. Covance (Acquired by Laboratory Corporation of America)
      • 6.3.8.1. Covance: Historical Revenue and Financial Performance, 2010-2013
      • 6.3.8.2. LabCorp Financial Performance, 2014-2017
      • 6.3.8.3. Strategies: Covance
        • 6.3.8.3.1. Agreement with Eli Lilly
        • 6.3.8.3.2. Agreement with Kellogg Company
        • 6.3.8.3.3. Early Stage Discovery Efforts
        • 6.3.8.3.4. Agreement with Sanofi
        • 6.3.8.3.5. Agreement with Bio Pontis Alliance
        • 6.3.8.3.6. Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)
        • 6.3.8.3.7. Launch of Mobile Health Solutions
        • 6.3.8.3.8. Business Expansion in the UK
        • 6.3.8.3.9. Business Expansion in Precision Medicine
        • 6.3.8.3.10. Acquisition of Chiltern
        • 6.3.8.3.11. Introduced Dedicated Offering
        • 6.3.8.3.12. Agreement with GlaxoSmithKline
        • 6.3.8.3.13. Focused Unit on Biologic Drug Development
        • 6.3.8.3.14. Acquisition of Sciformix Corporation
    • 6.3.9. Domainex
      • 6.3.9.1. Drug Pipeline
      • 6.3.9.2. TBK1/ IKKe-Inhibitors
      • 6.3.9.3. Methyltransferase (KMTS) Inhibitors
    • 6.3.10. GenScript Biotech Corporation
      • 6.3.10.1. GenScript: Revenue and Financial Analysis, 2017
      • 6.3.10.2. GenScript: Agreements and Partnerships
    • 6.3.11. Pharmaceutical Product Development (PPD)
      • 6.3.11.1. PPD: Agreements, Strategic Partnerships and Private Merger
        • 6.3.11.1.1. Partnership with GSK
        • 6.3.11.1.2. Partnership with Elan
        • 6.3.11.1.3. Acquisition of Acurian
        • 6.3.11.1.4. Collaboration with Charité-Universitätsmedizin Berlin
        • 6.3.11.1.5. Acquisition of RCT Logic's Exclusive License
        • 6.3.11.1.6. Partnership with ERT
        • 6.3.11.1.7. Partnership with Shin Nippon Biomedical Laboratories Ltd.
        • 6.3.11.1.8. Collaboration with HealthCore, Inc.
        • 6.3.11.1.9. Collaboration with CISYS LifeSciences
        • 6.3.11.1.10. Collaboration with Moderna Therapeutics
        • 6.3.11.1.11. Acquisition of Evidera
        • 6.3.11.1.12. Collaboration with Frenova Renal Research
        • 6.3.11.1.13. Collaboration with Quotient Sciences
    • 6.3.12. QuintilesIMS (IQVIA)
      • 6.3.12.1. QuintilesIMS: Historical Revenue and Financial Performance, 2013-2017
        • 6.3.12.2. QuintilesIMS: Strategic moves & developments
        • 6.3.12.2.1. Development Deal with Merck
        • 6.3.12.2.2. QuintilesIMS: Acquisition of Advion Bioanalytical Labs
        • 6.3.12.2.3. QuintilesIMS: Shedding Jobs
        • 6.3.12.2.4. Merger with IMS Health
        • 6.3.12.3. QuintilesIMS Sales Forecast, 2017-2028
    • 6.3.13. Selcia
      • 6.3.13.1. A Strong Natural Product Chemistry Track Record
      • 6.3.13.2. Selcia Product Portfolio
      • 6.3.13.3. Selcia Strategic Moves
        • 6.3.13.3.1. Collaboration with Cantab
        • 6.3.13.3.2. Initiative with the University of Edinburgh
        • 6.3.13.3.3. Collaboration with Janssen Pharmaceuticals Inc.
        • 6.3.13.3.4. Collaboration with Gilead Sciences, Inc.
        • 6.3.13.3.5. Collaboration with Parkinson's UK
    • 6.3.14. Viva Biotech (Shanghai) Ltd.
    • 6.3.15. WuXi Apptec
      • 6.3.15.1. WuxiTec Services & Solutions Offerings
      • 6.3.15.2. WuXiAppTec: Historical Revenue and Financial Performance, 2010-2014
      • 6.3.15.3. WuxiTec: Strategic Moves
        • 6.3.15.3.1. Acquisition of Next CODE Health
        • 6.3.15.3.2. Collaboration with Gilead Sciences, Inc.
        • 6.3.15.3.3. Collaboration with Eli Lilly and Company
        • 6.3.15.3.4. Acquisition of Crelux GmbH
        • 6.3.15.3.5. Collaboration with Pelago Bioscience
        • 6.3.15.3.6. Partnership with AutoGenomics
        • 6.3.15.3.7. Acquisition of HD Biosciences
        • 6.3.15.3.8. Acquisition of ResearchPoint Global
        • 6.3.15.3.9. Partnership with Mayo Clinic
        • 6.3.15.3.10. Collaboration with Regulus Therapeutics Inc.
        • 6.3.15.3.11. Business Expansion in the U.S.
        • 6.3.15.3.12. Partnership with Antengene Corporation

7. Qualitative Analysis of the Drug Discovery Outsourcing Market

  • 7.1. Drivers and Restraints in the Drug Discovery Outsourcing Market
  • 7.2. SWOT Analysis of the Drug Discovery Outsourcing Market, 2018-2028
    • 7.2.1. Strengths
      • 7.2.1.1. Cost Reduction: A Central Driver for Outsourcing
      • 7.2.1.2. Accelerating the Discovery of Drug Candidates
      • 7.2.1.3. Growth of Virtual Pharmaceutical Companies
      • 7.2.1.4. Reduction in R&D capacity Within Big Pharma
    • 7.2.2. Weaknesses
      • 7.2.2.1. Slowing Trajectory of Growth for R&D Spending
      • 7.2.2.2. Increasingly Saturated Market Requires Companies to Quickly Evolve
    • 7.2.3. Opportunities
      • 7.2.3.1. The Available Scope for the Expansion of CROs
      • 7.2.3.2. Targeted Therapies: Advances in Biologics and Orphan Drugs
      • 7.2.3.3. Increasing Development of Biologics and Biosimilars
    • 7.2.4. Threats
      • 7.2.4.1. A Competitive Market is Increasing Consolidation
      • 7.2.4.2. Threat of Private Public Alliances
      • 7.2.4.3. Intellectual Property Leaks
      • 7.2.4.4. Challenges of Technology Transfer
  • 7.3. Porter's Five Forces Analysis of the Drug Discovery Outsourcing Market
    • 7.3.1. Threat of New Entrants: Medium
    • 7.3.2. Power of Suppliers: Medium
    • 7.3.3. Threat of Substitutes: Medium
    • 7.3.4. Power of Buyers: High
    • 7.3.5. Rivalry Among Competitors: High

8. Conclusion

  • 8.1. Market Overview
  • 8.2. Lead Optimisation will be the Fastest Growing Sector
  • 8.3. The Drug Discovery Outsourcing Market in Emerging Market Shows Huge Gains
  • 8.4. Continued Growth in Alliances and Collaborations
  • 8.5. Concluding Remarks

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form
Back to Top